Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of A-101 Topical Solution for the Treatment of Common Warts

ClinicalTrials.gov ID: NCT03687372

Public ClinicalTrials.gov record NCT03687372. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts

Study identification

NCT ID
NCT03687372
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Enrollment
503 participants

Conditions and interventions

Conditions

Interventions

  • A-101 Drug
  • vehicle Other

Drug · Other

Eligibility (public fields only)

Age range
2 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 16, 2018
Primary completion
Jun 19, 2019
Completion
Sep 5, 2019
Last update posted
Oct 4, 2020

2018 – 2019

United States locations

U.S. sites
24
U.S. states
16
U.S. cities
24
Facility City State ZIP Site status
Aclaris Investigational Site Mobile Alabama 36608
Aclaris Investigational Site Hot Springs Arkansas 71913
Aclaris Investigational Site Fountain Valley California 92708
Aclaris Investigational site San Diego California 92123
Aclaris Investigational Site Aventura Florida 33180
Aclaris Investigational Site Jacksonville Florida 32256
Aclaris Investigational Site Miami Florida 33144
Aclaris Investigational Site Ocala Florida 34470
Aclaris Investigational Site Newnan Georgia 30263
Aclaris Investigational Site Indianapolis Indiana 46256
Aclaris Investigational Site Louisville Kentucky 40241
Aclaris Investigational Site Chestnut Hill Massachusetts 02467
Aclaris Investigational Site Warren Michigan 48088
Aclaris Investigational Site Fridley Minnesota 55432
Aclaris Investigational Site Las Vegas Nevada 89148
Aclaris Investigational Site Verona New Jersey 07044
Aclaris Investigational Site Broomall Pennsylvania 19008
Aclaris Investigational Site Fort Washington Pennsylvania 19034
Aclaris Investigational Site Charleston South Carolina 29407
Aclaris Investigational Site Greenville South Carolina 29607
Aclaris Investigational Site Austin Texas 78759
Aclaris Investigational Site Pflugerville Texas 78660
Aclaris Investigational Site San Antonio Texas 78213
Aclaris Investigational Site Spokane Washington 99202

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03687372, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 4, 2020 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03687372 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →